Home › Alzheimer's Disease › NCT07794670
Randomized Study to Evaluate the Effect of Obicetrapib in Participants With Preclinical Alzheimer's Disease
RecruitingPhase 2
A Phase 2b, Randomized, Double Blind, Placebo Controlled, Parallel Group Trial to Assess the Efficacy and Safety of Obicetrapib in Participants With Preclinical Alzheimer's Disease (SPINOZA Trial)
Who can join
Ages 55 to 85 · All sexes
Full eligibility criteria
Inclusion Criteria: * participants with preclinical AD Exclusion Criteria: * APOE genotype not meeting protocol-defined eligibility criteria
About the study
A study evaluating Obicetrapib in adults potentially at risk for Preclinical Alzheimer's Disease
What is being tested
- Obicetrapib 10 mg (drug)
- Matching placebo tablets (drug)
Sponsor: NewAmsterdam Pharma · Participants: 400 · Started: 2026-09
Contact the study team
Official record on ClinicalTrials.gov — NCT07794670
Locations in the U.S.
| Tennessee | K2 Medical Research, Nashville |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.